<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have studied 215 male patients (aged 45-97 years) whose sole cytogenetic abnormality was clonal loss of the Y chromosome in metaphase cells from unstimulated cultures </plain></SENT>
<SENT sid="1" pm="."><plain>The patients comprised a control group with no evidence of <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic disease</z:e> and four disease case groups: 1) <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>, <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>), <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation, and <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>; 2) <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo>; 3) <z:hpo ids='HP_0005547'>myeloproliferative disorder</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>), <z:hpo ids='HP_0011010'>chronic</z:hpo> granulocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and <z:hpo ids='HP_0001901'>polycythemia</z:hpo> vera; and 4) B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The frequency of cells with Y loss increased with age and was significantly greater in cases than in controls, but it was not correlated with survival or with prior therapy </plain></SENT>
<SENT sid="3" pm="."><plain>The frequency of cases with a -Y clone was 6.3% of male karyotypes and represented 16.4% of <z:hpo ids='HP_0000001'>all</z:hpo> abnormal male cytogenetic reports </plain></SENT>
<SENT sid="4" pm="."><plain>Much of the difference between cases and controls appears to be accounted for by a greater frequency of cases with &gt; 75% Y loss </plain></SENT>
<SENT sid="5" pm="."><plain>A value of 81% chromosome Y loss maximized the combined sensitivity (28%) and specificity (100%) for predicting disease status, but a 75% cutoff provided the best estimate of disease risk </plain></SENT>
<SENT sid="6" pm="."><plain>Even in older males, if &gt; 75% of metaphase cells are 45,X,-Y, they probably represent a disease-associated clonal population, and it is possible that the critical genetic change is not visible through the microscope </plain></SENT>
<SENT sid="7" pm="."><plain>This observation is true for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MPD</z:e>, B-cell disease, and especially <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>The prognostic association of Y chromosome loss for survival appears to be neutral or favorable </plain></SENT>
<SENT sid="9" pm="."><plain>Genes Chromosomes <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> 27:11-16, 2000 </plain></SENT>
</text></document>